Shanghai Henlius Biotech (HKG:2696) obtained approval for a new indication of its serplulimab injection from the European Commission, according to a Thursday Hong Kong bourse filing.
The approved indication is for serplulimab in combination with carboplatin and nab-paclitaxel for the first-line treatment of adults with unresectable, locally advanced or metastatic squamous non-small cell lung carcinoma.
The new indication has been approved in all EU member states as well as in Iceland, Liechtenstein, and Norway.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments